Ana Henriques

Ana Henriques

Auto-generated profile, based on publicly available information

Ana Henriques

Blood and Transplantation Center of Coimbra, Portuguese Institute of Blood and Transplantation, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2013 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
ARAndreia Ribeiro
Andreia Ribeiro
Paula LaranjeiraPaula Laranjeira
Paula Laranjeira
SMSandrine Mendes
Sandrine Mendes
Isabel VeladaIsabel Velada
Isabel Velada
CLCristiana Leite
Cristiana Leite
APArtur Paiva
Artur Paiva
Introduction: The ability to self-renew, be easily expanded in vitro and differentiate into different mesenchymal tissues, render mesenchymal stem cells (MSCs) an attractive therapeutic method for degenerative diseases. The subsequent discovery of their immunosuppressive ability encouraged clinical trials in graft-versus-host disease and auto-immune diseases. Despite sharing several immunophenotypic characteristics and functional capabilities, the differences between MSCs arising from different tissues are still unclear and the published data are conflicting. Methods: Here, we evaluate the influence of human MSCs derived from umbilical cord matrix (UCM), bone marrow (BM) and adipose tissue (AT), co-cultured with phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (MNC), on T, B and natural killer (NK) cell activation; T and B cells’ ability to acquire lymphoblast characteristics; mRNA expression of interleukin-2 (IL-2), forkhead box P3 (FoxP3), T-bet and GATA binding protein 3 (GATA3), on purified T cells, and tumor necrosis factor-alpha (TNF-α), perforin and granzyme B on purified NK cells. Results: MSCs derived from all three tissues were able to prevent CD4+ and CD8+ T cell activation and acquisition of lymphoblast characteristics and CD56dim NK cell activation, wherein AT-MSCs showed a stronger inhibitory effect. Moreover, AT-MSCs blocked the T cell activation process in an earlier phase than BM- or UCM-MSCs, yielding a greater proportion of T cells in the non-activated state. Concerning B cells and CD56bright NK cells, UCM-MSCs did not influence either their activation kinetics or PHA-induced lymphoblast characteristics, conversely to BM- and AT-MSCs which displayed an inhibitory effect. Besides, when co-cultured with PHA-stimulated MNC, MSCs seem to promote Treg and Th1 polarization, estimated by the increased expression of FoxP3 and T-bet mRNA within purified activated T cells, and to reduce TNF-α and perforin production by activated NK cells. Conclusions: Overall, UCM-, BM- and AT-derived MSCs hamper T cell, B cell and NK cell-mediated immune response by preventing their acquisition of lymphoblast characteristics, activation and changing the expression profile of proteins with an important role in immune function, except UCM-MSCs showed no inhibitory effect on B cells under these experimental conditions. Despite the similarities between the three types of MSCs evaluated, we detect important differences that should be taken into account when choosing the MSC source for research or therapeutic purposes.

2 July 2009 in Blood
Verified
Journal Article
Closed access
PDF file
WNWendy G. Nieto
Wendy G. Nieto
JAJulia Almeida
Julia Almeida
ARAlfonso Romero
Alfonso Romero
CTCristina Isabel Gonçalves Grunho Teodosio
Cristina Isabel Gonçalves Grunho Teodosio
ALAntonio López
Antonio López
TMthe Primary Health Care Group of Salamanca for the Study of MBL5
the Primary Health Care Group of Salamanca for the Study of MBL5
Monoclonal B-cell lymphocytosis (MBL) indicates the presence of less than 5 × 109/L circulating monoclonal B cells in otherwise healthy subjects. Recently, it has been reported that circulating chronic lymphocytic leukemia (CLL)–like B cells can be detected using 4- or 5-multicolor flow cytometry in 5% to 7% of adults with normal lymphocyte counts. We investigated the frequency of circulating monoclonal B cells in 608 healthy subjects older than 40 years with normal blood counts, using a highly sensitive 8-color flow cytometry approach and systematic screening for total PB leukocyte count higher than 5 × 106. We show that the frequency of PB monoclonal B cells is markedly higher than previously reported (12% for CLL-like B cells, found at frequencies of 0.17 ± 0.13 × 109 cells/L), the incidence progressively increasing with age. Most cases (62%) showed clonal B-cell levels below the maximum sensitivity of the techniques described by others (< 0.01%), supporting the notion that detection of MBL may largely depend on the sensitivity of the flow cytometry approach used.

1 January 2010 in Cellular Immunology
Verified
Journal Article
Closed access
AHAna Henriques
Ana Henriques
LILuís Sousa Inês
Luís Sousa Inês
MCMaura Couto
Maura Couto
SPSusana Pedreiro
Susana Pedreiro
CSCatarina Santos
Catarina Santos
APArtur Paiva
Artur Paiva

2 February 2013 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
AHAna Henriques
Ana Henriques
LTLuís Teixeira
Luís Teixeira
LILuís Sousa Inês
Luís Sousa Inês
TCTiago Carvalheiro
Tiago Carvalheiro
AGAna Gonçalves
Ana Gonçalves
APArtur Paiva
Artur Paiva

17 May 2011 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
JMJosé Mário Morgado
José Mário Morgado
LRLuis Rama
Luis Rama
ISIsabel Silva
Isabel Silva
MIMaria de Jesus Inácio
Maria de Jesus Inácio
AHAna Henriques
Ana Henriques
ATAna Maria Teixeira
Ana Maria Teixeira

19 September 2012 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
LRLuis Rama
Luis Rama
ATAna Maria Teixeira
Ana Maria Teixeira
AMAlice Matos
Alice Matos
GBGrasiely Faccin Borges
Grasiely Faccin Borges
AHAna Henriques
Ana Henriques
APArtur Paiva
Artur Paiva